Abstract
Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one kind of oncolytic adenovirus with E1B-55KD and partial E3 deleted developed by Shanghai Sunwaybio. From 2000-2004, phase I to phase III clinical trials for treating head and neck cancer were conducted in China. Clinical data show that H101 is well tolerable and has good efficacy when combined with chemotherapy in some cancer treatment modalities. We review the clinical results and relative issues of H101 in treating cancer and discuss approaches and possible improvements for the future. Information on other oncolytic viruses developing in China is also provided.
Keywords: Oncolytic virus, clinical trial, China, H101, adenovirus
Current Cancer Drug Targets
Title: Clinical Trials with Oncolytic Adenovirus in China
Volume: 7 Issue: 2
Author(s): Wang Yu and Hu Fang
Affiliation:
Keywords: Oncolytic virus, clinical trial, China, H101, adenovirus
Abstract: Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one kind of oncolytic adenovirus with E1B-55KD and partial E3 deleted developed by Shanghai Sunwaybio. From 2000-2004, phase I to phase III clinical trials for treating head and neck cancer were conducted in China. Clinical data show that H101 is well tolerable and has good efficacy when combined with chemotherapy in some cancer treatment modalities. We review the clinical results and relative issues of H101 in treating cancer and discuss approaches and possible improvements for the future. Information on other oncolytic viruses developing in China is also provided.
Export Options
About this article
Cite this article as:
Yu Wang and Fang Hu, Clinical Trials with Oncolytic Adenovirus in China, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058817
DOI https://dx.doi.org/10.2174/156800907780058817 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Hypoxia and Fetal Heart Development
Current Molecular Medicine Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry The Development of Antimicrobial Peptides as New Antibacterial Drugs
Current Protein & Peptide Science The Potential Role of Radiation Therapy in Bowens Disease: A Review of the Current Literature
Reviews on Recent Clinical Trials A Comprehensive Review on Nanotechnology-Based Innovations in Topical Drug Delivery for the Treatment of Skin Cancer
Current Pharmaceutical Design An Evaluation of the Antioxidant and Anticancer Properties of Complex Compounds of Copper (II), Platinum (II), Palladium (II) and Ruthenium (III) for Use in Cancer Therapy
Mini-Reviews in Medicinal Chemistry